Repare Therapeutics (RPTX) announced that the Company has received an approximately $1.5 M research service payment from Ono Pharmaceutical (OPHLY). The payment reflects achievement of a specified research trigger, under the companies’ 2019 Strategic Partnership Agreement. Under the terms of the Ono Agreement, Repare is primarily responsible for carrying out research activities for its Pol program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan. "This reflects an important milestone in our RP-2119 Pol program, as we undertake our IND-enabling studies and prepare for our previously guided initiation of clinical trials in the summer of 2023," said Kim Seth, Chief Business Officer of Repare.
Published first on TheFly
